The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.

In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.

• Drug: Lamivudine/Zidovudine
• Drug: Abacavir sulfate
• Drug: Amprenavir

Inclusion Criteria

Patients must have:

• CD4 count greater than 50 cells/mm3.
• HIV RNA less than 50,000 copies/ml.
• No active AIDS (excluding CD4 count less than 200 cells/mm3).
• Ability to comply with dosing schedule and protocol evaluations.

Prior Medication:

Allowed:

AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

• Active AIDS (not excluding CD4 count less than 200).
• Malabsorption syndrome affecting drug absorption.
• Serious medical condition that would compromise safety of the patient.

Concurrent Medication:

Excluded:

• AZT or NNRTIs.
• More than 1 week treatment with any protease inhibitor.
• Enrollment in any other investigational drug protocol.

Patients with the following prior conditions are excluded:

History of clinically relevant pancreatitis or hepatitis within the past 6 months.

Required:

Antiretroviral therapy with either single or double reverse transcriptase inhibitors.